Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto rats

Journal of Hypertension

Volumn 17, Issue 4, 1999, Pages 507-512

  Calhoun, David A ^a,b   Sutao, Zhu ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b 520 Ziegler Research Building ^*  (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Calcium channel blocker; Lumbar sympathetic nerve activity; Sympathetic activation

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENALAPRILAT; NICARDIPINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; HEART RATE; HYPERTENSION; MALE; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE;

EID: 0033033227     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917040-00008     Document Type: Article

References (14)

1. 1 Van Zwieten PA, Hansson L, Epstein M. Slowly acting calcium antagonists and their merits. Blood Press 1997; 6:78-80.
2. 2 Psaty BM, Heckbert SR, Koapsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihyper tensive drug therapies. JAMA 1995; 274:620-625.
3. 3 Pahor M, Guralnik JM, Corti M-C, Foley DJ, Carbonin P, Havlik RJ. Longterm survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43:1191-1197.
4. 4 Estaio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N. Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998; 33:645-653.
5. 5 Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.
6. 6 Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-1331.
7. 7 Kent BB, Drano JW, Blumenstein B, Manning JW. A mathematical model to assess changes in the baroreceptor reflex. Cardiology 1972; 57:295-310.
8. 8 Takishita S, Muratani H, Sesoko S, Teruya H, Tozawa M, Fukiyama K, et al. Short-term effects of angiotensin II blockade on renal blood flow and sympathetic activity in awake rats. Hypertension 1994; 24:445-450.
9. 9 Kumagai H, Suzuki H, Ichikawa M, Nishizawa M, Ryuzaki M, Kumagai K, et al. Different responses of renal blood flow and sympathetic nerve activity to captopril and nicardipine in conscious renal hypertensive rabbits. J Cardiovasc Pharmacol 1995; 25:57-64.
10. 10 Kumagai K, Suzuki H, Ryuzaki M, Kumagai H, Ichikawa M, Jimbo M, et al. Effects of antihypertensive agents on arterial baroreceptor reflexes in conscious rats. Hypertension 1992; 20:701-709.
11. 11 Damase-Michel C, Montastruc JL, Montastruc P. Central cardiovascular actions of calcium channel antagonists in dogs. Fundam Clin Pharmacol 1989; 3 (Suppl 3):57s-64s.
12. 12 Taddei S, Virdis A, Mattei P, Duranti P, Favilla S, Salvetti A. Vascular reninangiotensin system and sympathetic nervous system activity in human hypertension. J Cardiovasc Pharmacol 1994; 23 (Suppl 1):S9-S14.
13. 13 Mancia G, van Zwieten PA. How safe are calcium antagonists in hypertension and coronary heart disease? J Hypertens 1996; 14:13-17.
14. 14 Staessen JA, Fagard F, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al., for the Systolic Hypertension in Europe (Syst-Eur) Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension, Lancet 1997; 350:757-764.